Meta (NASDAQ: META) Bets Its AI Agent Muse Can Overcome Decades Of Trust Baggage
Meta Platforms (NASDAQ: META) is staking its artificial intelligence future on Muse, a newly...
Read More
Invesco Aerospace & Defense ETF (NYSEARCA: PPA) Offers Single-Ticker Defense Exposure But Concentrates Nearly 30% In Just Four Stocks
Defense budgets are expanding rapidly on both sides of the Atlantic, turning aerospace and defense...
Read More
UBS Slashes Oklo (NYSE: OKLO) Stock Price Target To $41, But Air Force Microreactor Deal Could Drive Commercial Breakthrough
UBS cut its price target on Oklo (NYSE: OKLO) to $41 from $55 on Friday, while maintaining a...
Read More
StoneX Initiates Buy Coverage On Enterprise Financial Services Corp Preferred Stock (NASDAQGS: EFSCP) As Analyst Sentiment Turns Bullish
StoneX initiated coverage of Enterprise Financial Services Corp (NASDAQGS: EFSCP) preferred stock...
Read More
US And China Agree To Lower Tariffs On $30 Billion In Goods Following Three-Day Washington Summit
The United States and China have agreed to reduce tariffs on $30 billion worth of traded goods...
Read More
Google (NASDAQ: GOOGL) Pilots Direct Flipkart Purchases Through Gemini And AI Mode Ahead Of India’s Festive Shopping Season
Google (NASDAQ: GOOGL) has begun testing a feature that allows shoppers in India to purchase...
Read More
Trump Media & Technology Group (NASDAQ: DJT) Stock Faces Sharp Valuation Gap As White House Media Access Ruling Puts Political Platforms In Focus
A federal judge’s decision to restore White House press access for CNN, MS NOW, and Politico...
Read More
Bitmine (BTMN) Chair Tom Lee Predicts Ethereum Will Break Past $5,000 To Set New All-Time High
Bitmine Immuable Inc. (NASDAQ: BTMN) Chairman Tom Lee is making one of his boldest calls yet,...
Read More
Rolls-Royce Holdings (LON: RR.) Outpaces FTSE 100 As Philippine Airlines Engine Deal Supports Sentiment
Rolls-Royce Holdings (LON: RR.) climbed 0.46 percent to GBX 1,490.80 on September 25, 2026,...
Read More
Eli Lilly (NYSE: LLY), Novo Nordisk And Novartis Bet On Discovery Platforms Over Late-Stage Pipeline Assets
Big pharma’s dealmaking appetite remains strong in 2026, but the strategic logic has shifted...
Read More